| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1714 | 2017 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1183 | 2017 |
| Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra, K Kerr, ... Annals of Oncology 27, v1-v27, 2016 | 994 | 2016 |
| Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, JS Lee, MJ Hochmair, ... New England Journal of Medicine 379 (21), 2027-2039, 2018 | 883 | 2018 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 547 | 2018 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 544 | 2018 |
| Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) SV Liu, M Reck, AS Mansfield, T Mok, A Scherpereel, N Reinmuth, ... Journal of Clinical Oncology 39 (6), 619-630, 2021 | 446 | 2021 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 417 | 2017 |
| Brigatinib versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trial DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Journal of Clinical Oncology 38 (31), 3592-3603, 2020 | 298 | 2020 |
| Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Journal of Thoracic Oncology 16 (12), 2091-2108, 2021 | 230 | 2021 |
| Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial DA Fennell, S Ewings, C Ottensmeier, R Califano, GG Hanna, K Hill, ... The Lancet Oncology 22 (11), 1530-1540, 2021 | 205* | 2021 |
| Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer A Prelaj, R Tay, R Ferrara, N Chaput, B Besse, R Califano European journal of cancer 106, 144-159, 2019 | 193 | 2019 |
| Pembrolizumab plus ipilimumab or placebo for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%: randomized, double-blind phase III KEYNOTE-598 study M Boyer, MAN Şendur, D Rodríguez-Abreu, K Park, DH Lee, I Çiçin, ... Journal of Clinical Oncology 39 (21), 2327-2338, 2021 | 188 | 2021 |
| Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma L Khoja, P Lorigan, C Zhou, M Lancashire, J Booth, J Cummings, ... Journal of Investigative Dermatology 133 (6), 1582-1590, 2013 | 156 | 2013 |
| A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours OA Khan, M Gore, P Lorigan, J Stone, A Greystoke, W Burke, ... British journal of cancer 104 (5), 750-755, 2011 | 152 | 2011 |
| Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial AS Mansfield, A Każarnowicz, N Karaseva, A Sánchez, R De Boer, ... Annals of oncology 31 (2), 310-317, 2020 | 144 | 2020 |
| CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations E Felip, A Ardizzoni, T Ciuleanu, M Cobo, K Laktionov, M Szilasi, ... European Journal of Cancer 127, 160-172, 2020 | 139 | 2020 |
| Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK R Califano, N Tariq, S Compton, DA Fitzgerald, CA Harwood, R Lal, ... Drugs 75, 1335-1348, 2015 | 138 | 2015 |
| Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) young oncologists committee burnout survey S Banerjee, R Califano, J Corral, E de Azambuja, L De Mattos-Arruda, ... Annals of Oncology 28 (7), 1590-1596, 2017 | 137 | 2017 |
| Management of small cell lung cancer: recent developments for optimal care R Califano, AZ Abidin, R Peck, C Faivre-Finn, P Lorigan Drugs 72, 471-490, 2012 | 100 | 2012 |
Marina Chiara GarassinoThe University of Chicago在 medicine.bsd.uchicago.edu 的电子邮件经过验证
